ES2192495A1 - Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina) - Google Patents

Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina)

Info

Publication number
ES2192495A1
ES2192495A1 ES200200760A ES200200760A ES2192495A1 ES 2192495 A1 ES2192495 A1 ES 2192495A1 ES 200200760 A ES200200760 A ES 200200760A ES 200200760 A ES200200760 A ES 200200760A ES 2192495 A1 ES2192495 A1 ES 2192495A1
Authority
ES
Spain
Prior art keywords
acadesine
lymphoma
cells
cell
riboside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200200760A
Other languages
English (en)
Other versions
ES2192495B1 (es
Inventor
Blanco Jose Manuel Lopez
Moya Clara Campas
Santano Juan Gil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat Autonoma de Barcelona UAB
Universitat de Barcelona UB
Original Assignee
Universitat Autonoma de Barcelona UAB
Universitat de Barcelona UB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200200760A priority Critical patent/ES2192495B1/es
Application filed by Universitat Autonoma de Barcelona UAB, Universitat de Barcelona UB filed Critical Universitat Autonoma de Barcelona UAB
Priority to PT03709839T priority patent/PT1508333E/pt
Priority to SI200330380T priority patent/SI1508333T1/sl
Priority to PCT/ES2003/000130 priority patent/WO2003080076A1/es
Priority to ES03709839T priority patent/ES2264525T3/es
Priority to DK03709839T priority patent/DK1508333T3/da
Priority to MXPA04009191A priority patent/MXPA04009191A/es
Priority to EP03709839A priority patent/EP1508333B1/en
Priority to CA002479674A priority patent/CA2479674C/en
Priority to KR1020047014654A priority patent/KR101007044B1/ko
Priority to US10/508,305 priority patent/US7560435B2/en
Priority to JP2003577902A priority patent/JP5085004B2/ja
Priority to AT03709839T priority patent/ATE326976T1/de
Priority to DE60305485T priority patent/DE60305485T2/de
Priority to AU2003214275A priority patent/AU2003214275B2/en
Publication of ES2192495A1 publication Critical patent/ES2192495A1/es
Application granted granted Critical
Publication of ES2192495B1 publication Critical patent/ES2192495B1/es
Priority to CY20061101133T priority patent/CY1105417T1/el
Priority to JP2010087046A priority patent/JP2010180230A/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Nuevo uso terapéutico del ribósido de 5-aminoimidazol-4- carboxamida (acadesina). La acadesina (también conocida como AICA-ribósido o AICAR) no inhibe la apoptosis en linfocitos, como se podría esperar, pero induce apoptosis en las células B de pacientes con leucemia linfática crónica de tipo B(B-CLL, B-cell lymphocytic leukemia), mientras que las células T no se ven afectadas. Estos resultados inesperados hacen de la acadesina y sus bioprecursores (p.ej. sus mono-, di- y tri-5''-fosfatos) unos agentes terapéuticos útiles para la leucemia linfática crónica de tipo B (B-CLL) en humanos. El efecto diferencial de la acadesina en linfocitos B y T es una característica importante de la invención, porque significa que los efectos secundarios adversos (inmunosupresión) son pequeños cuando se utiliza la acadesina como agente antileucémico. Esto representa una ventaja terapéutica sobre el uso de la cladribina, la fludarabina u otros nucleósidos conocidos en la técnica.
ES200200760A 2002-03-21 2002-03-21 Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina). Expired - Fee Related ES2192495B1 (es)

Priority Applications (17)

Application Number Priority Date Filing Date Title
ES200200760A ES2192495B1 (es) 2002-03-21 2002-03-21 Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
AT03709839T ATE326976T1 (de) 2002-03-21 2003-03-20 Neue therapeutische verwendung des ribosid von 5- aminoimidazol-4- carbonsäureamid (acadesin)
PCT/ES2003/000130 WO2003080076A1 (es) 2002-03-21 2003-03-20 Nuevo uso terapéutico del ribósido de 5-aminoimidazol-4-carboxamida (acadesina)
ES03709839T ES2264525T3 (es) 2002-03-21 2003-03-20 Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
DK03709839T DK1508333T3 (da) 2002-03-21 2003-03-20 Ny terapeutisk anvendelse af ribosoid af 5-aminoimidazol-4-carboxamid (Acadesin)
MXPA04009191A MXPA04009191A (es) 2002-03-21 2003-03-20 Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
EP03709839A EP1508333B1 (en) 2002-03-21 2003-03-20 Novel therapeutic use of riboside of 5-aminoimidazole-4- carboxamide (acadesine)
CA002479674A CA2479674C (en) 2002-03-21 2003-03-20 New therapeutic use of 5-aminoimidazole-4-carboxamide riboside (acadesine)
PT03709839T PT1508333E (pt) 2002-03-21 2003-03-20 Nova utilizacao terapeutica de ribosido de 5- aminoimidazol-4-carboxamida ( acadesina )
US10/508,305 US7560435B2 (en) 2002-03-21 2003-03-20 Therapeutic use of riboside of 5-aminoimidazole-4-carboxamide (acadesine)
JP2003577902A JP5085004B2 (ja) 2002-03-21 2003-03-20 ５−アミノイミダゾール−４−カルボキサミドリボシド（アカデシン）の新規な治療上の使用
SI200330380T SI1508333T1 (sl) 2002-03-21 2003-03-20 Nova terapevtska uporaba ribozida 5-aminoimidazol-4-karboksamida (akadezina)
DE60305485T DE60305485T2 (de) 2002-03-21 2003-03-20 Neue therapeutische verwendung des ribosid von 5-aminoimidazol-4- carbonsäureamid (acadesin)
AU2003214275A AU2003214275B2 (en) 2002-03-21 2003-03-20 Novel therapeutic use of riboside of 5-aminoimidazole-4-carboxamide (acadesine)
KR1020047014654A KR101007044B1 (ko) 2002-03-21 2003-03-20 5-아미노이미다졸-4-카르복사마이드리보사이드(5-ａｍｉｎｏｉｍｉｄａｚｏｌｅ-4-ｃａｒｂｏｘａｍｉｄｅ ｒｉｂｏｓｉｄｅ (아카데신))의 신규한 치료용도
CY20061101133T CY1105417T1 (el) 2002-03-21 2006-08-11 Νεα θepαπευτικη χρηση ριβοσιδιου 5-αμινοϊμιδαζολο-4-καρβοξαμιδιου (ακαδεσινη)
JP2010087046A JP2010180230A (ja) 2002-03-21 2010-04-05 ５−アミノイミダゾール−４−カルボキサミドリボシド（アカデシン）の新規な治療上の使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200200760A ES2192495B1 (es) 2002-03-21 2002-03-21 Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).

Publications (2)

Publication Number Publication Date
ES2192495A1 true ES2192495A1 (es) 2003-10-01
ES2192495B1 ES2192495B1 (es) 2005-02-16

Family

ID=28051973

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200200760A Expired - Fee Related ES2192495B1 (es) 2002-03-21 2002-03-21 Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
ES03709839T Expired - Lifetime ES2264525T3 (es) 2002-03-21 2003-03-20 Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES03709839T Expired - Lifetime ES2264525T3 (es) 2002-03-21 2003-03-20 Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).

Country Status (15)

Country Link
US (1) US7560435B2 (es)
EP (1) EP1508333B1 (es)
JP (2) JP5085004B2 (es)
KR (1) KR101007044B1 (es)
AT (1) ATE326976T1 (es)
AU (1) AU2003214275B2 (es)
CA (1) CA2479674C (es)
CY (1) CY1105417T1 (es)
DE (1) DE60305485T2 (es)
DK (1) DK1508333T3 (es)
ES (2) ES2192495B1 (es)
MX (1) MXPA04009191A (es)
PT (1) PT1508333E (es)
SI (1) SI1508333T1 (es)
WO (1) WO2003080076A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2594273A1 (en) 2005-03-28 2013-05-22 Pericor Therapeutics, Inc. Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
US20070082859A1 (en) * 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
WO2008086341A1 (en) * 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
WO2009036414A1 (en) * 2007-09-13 2009-03-19 University Of South Florida Method of selectively inhibiting pkciota
WO2010040110A1 (en) * 2008-10-03 2010-04-08 Pericor Therapeutics, Inc. Methods and compositions for treatment of acute heart failure
WO2010147663A1 (en) * 2009-06-16 2010-12-23 Massechusetts Institute Of Technology Methods and compositions for inhibiting proliferation of aneuploid cells
US8895520B2 (en) 2011-10-26 2014-11-25 Universite Nice Sophia Antipolis Method for treating a human patent suffering from Myeloid Neoplasias using 5-aminoimidazole-4-carboxamide
KR101498942B1 (ko) * 2012-09-06 2015-03-05 한올바이오파마주식회사 결핵 치료용 약학적 조성물
WO2017123911A1 (en) * 2016-01-15 2017-07-20 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
JP7376951B2 (ja) * 2018-08-06 2023-11-09 スカイラーク バイオサイエンス エルエルシー Ａｍｐ活性化プロテインキナーゼ活性化化合物およびその使用
US11779590B2 (en) 2020-10-30 2023-10-10 Skylark Bioscience Llc AMP-activated protein kinase activating compounds and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238110A (en) * 1962-07-18 1966-03-01 Ajinomoto Kk Method for producing 5-amino-4-imidazolecarboxamide riboside
GB1011346A (en) * 1963-08-28 1965-11-24 Pfizer & Co C Flavour enhancer and method for its production
US3173848A (en) * 1963-11-05 1965-03-16 Pfizer & Co C Production of 5-amino-4-imidazole-carboxamide riboside and related compounds
DE1645976A1 (de) * 1966-06-18 1971-01-21 Ajinomoto Kk Verfahren zur Herstellung von Adenosin und 2',3'-O-Isopropylidenadenosin
JPS5461195A (en) * 1977-10-21 1979-05-17 Takeda Chem Ind Ltd N2-substituted phenyl-2,6-diaminonebularin
JPS5461194A (en) * 1977-10-21 1979-05-17 Takeda Chem Ind Ltd Preparation of n22substituted 2*66diaminonebularin
JPS55130998A (en) * 1979-04-02 1980-10-11 Takeda Chem Ind Ltd N2-substituted 2,6-diaminonebularin
US4912092A (en) * 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
JPH0660193B2 (ja) * 1988-02-29 1994-08-10 ヤマサ醤油株式会社 イミダゾールヌクレオシド誘導体
CA1317588C (en) * 1988-02-29 1993-05-11 Tohru Ueda Imidazole derivatives, process for production thereof, and use thereof
US5082829A (en) * 1989-01-24 1992-01-21 Gensia Pharmaceuticals AICA riboside prodrugs
CA2008325A1 (en) 1989-01-24 1990-07-24 Harry E. Gruber Method and compounds for aica riboside delivery and for lowering blood glucose
US5132291A (en) * 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
US5200525A (en) * 1989-01-24 1993-04-06 Gensia Pharmaceuticals Anti-seizure compounds
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5187162A (en) * 1989-09-15 1993-02-16 Gensia Pharmaceuticals Methods of treating neurodegenerative conditions
US5777100A (en) * 1990-08-10 1998-07-07 Gensia Inc. AICA riboside analogs
US5236908A (en) * 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
WO1993003734A1 (en) 1991-08-23 1993-03-04 Gensia, Inc. Method for lowering blood lipid levels
IL103294A0 (en) * 1991-09-30 1993-05-13 Gensia Pharma Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
AU2001268236A1 (en) 2000-06-06 2001-12-17 Trustees Of Boston University Use of aicar and related compounds
AU2001269785A1 (en) 2000-06-09 2001-12-17 Brigham Young University Method of treatment of obesity and paralyzed muscle and ergogenic aids
WO2001097816A1 (en) 2000-06-16 2001-12-27 Brigham Young University Use of amp kinase activators for treatment of type 2 diabetes and insulin resistance
WO2002009726A1 (en) 2000-07-31 2002-02-07 Trustees Of Boston University Methods of treating conditions associated with insulin resistance with aicar, (5-amino-4-imidazole carboxamide riboside) and related compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MATSUDA, A. et al.: The design, synthesis and antileukemic activity of 5-alkynyl-1-beta-ribofuranosylimidazole-4- carboxamides. Chem. Pharm. Bull., 1988, Vol. 36, nö 7, páginas 2730-2733. Página 2730, fórmula I. *
MONTGOMERY, J.A. et al.: 1-glycosyl derivatives of 5-aminoimidazole-4-carboxamide. J. of Med. Chem., 1972, Vol. 15, nö 12, páginas 1334-1336. Página 1334, columna 2, fórmula nö 5. *
WITKOWSKI, J.T. et al.: Design, synthesis and broad spectrum antiviral activity of 1-beta-D-ribofuranosyl-1,2,4-triazole-3- carboxamide and related nucleosides. J. of Med. Chem., 1972, Vol. 15, nö 11, páginas 1150-1153. Fórmula 3. *

Also Published As

Publication number Publication date
JP2010180230A (ja) 2010-08-19
US7560435B2 (en) 2009-07-14
KR20050115820A (ko) 2005-12-08
CA2479674C (en) 2009-12-22
JP5085004B2 (ja) 2012-11-28
ES2264525T3 (es) 2007-01-01
JP2005520851A (ja) 2005-07-14
US20050233987A1 (en) 2005-10-20
MXPA04009191A (es) 2004-11-26
ATE326976T1 (de) 2006-06-15
CA2479674A1 (en) 2003-10-02
CY1105417T1 (el) 2010-04-28
DK1508333T3 (da) 2006-09-25
KR101007044B1 (ko) 2011-01-12
AU2003214275B2 (en) 2006-02-09
DE60305485D1 (de) 2006-06-29
DE60305485T2 (de) 2007-03-15
EP1508333B1 (en) 2006-05-24
ES2192495B1 (es) 2005-02-16
EP1508333A1 (en) 2005-02-23
AU2003214275A1 (en) 2003-10-08
SI1508333T1 (sl) 2006-10-31
PT1508333E (pt) 2006-10-31
WO2003080076A1 (es) 2003-10-02

Similar Documents

Publication Publication Date Title
CY1105417T1 (el) Νεα θepαπευτικη χρηση ριβοσιδιου 5-αμινοϊμιδαζολο-4-καρβοξαμιδιου (ακαδεσινη)
DE3854297D1 (de) Nucleoside und nucleotide mit antiviraler, antitumoraler, antimetastatischer sowie immunstimulierender wirkung.
EP2955190A3 (en) Chemical compounds
DE59610678D1 (de) Vorrichtung für die knochenchirurgie
WO2003062255A3 (en) Sugar modified nucleosides as viral replication inhibitors
EP1494668A4 (en) USE OF BENZIMIDAZOL ANALOGUE IN THE TREATMENT OF CELL PROLIFERATION
HK1074663A1 (en) Protective device
Uberti et al. The effect of nucleosides and deoxycoformycin on adenosine and deoxyadenosine inhibition of human lymphocyte activation
TW353803B (en) Processing apparatus for substrates to be processed
NO963029L (no) Anvendelse av IL-10 for å stimulere cytologisk aktivitet av enkjernete celler i perifert blod
HUP0300219A2 (hu) L-nukleozidokat, L-nukleotidokat és analógjaikat tartalmazó készítmények és alkalmazásuk
AU2003301589A8 (en) Purine nucleosides
FI932868A0 (fi) 2'-deoxi-2'2'-difluor(2,6,8-substituerade) purinnukleosider med virus-och cancerhaemmande aktivitet, samt mellanprodukter
NO954880L (no) Cytidin deaminase
CL2009000183A1 (es) Uso de nucleotidos de uridina, guanosina, citidina, timidina y adenosina en una composicion de alimento para peces para mejorar el desarrollo intestinal del pez.(divisional 2787-00).
WO2003106681A3 (de) Antisense oligonukleotide gegen pim1
GR852029B (es)
MY131925A (en) Absorbent article with liquid acquisition layer
DE50214504D1 (de) Sattelunterlage
AU2003292970A1 (en) Downhill ski
WO2001066118A8 (en) 4'-thio-l-xylo furanosyl nucleosides, precursors thereof, preparation and use thereof
Kefford et al. S-adenosylhomocysteine hydrolase inhibition in deoxyadenosine-treated human T-lymphoblasts and resting peripheral blood lymphocytes
YU58600A (sh) Oblik vi 5,6-dihloro-2-(izopropilamino)-1-(beta-l-ribofuranozil)-1h-benzimidazola
Kohgo et al. Synthesis of 4′-substituted nucleosides and their biological evaluation
BE1003106A5 (fr) Appareil et procede d'avance de feuilles dans des directions multiples.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031001

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2192495B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20220628